イスラエルのImagene AI、第一三共とがん創薬で提携

The partnership between Imagene AI and Daiichi Sankyo represents a convergence of Israeli AI innovation in drug discovery with Japan's major pharmaceutical development capabilities. Imagene AI's platform consolidates multiple data types—pathology images, molecular profiles, and clinical outcomes—into a unified analytical framework, enabling the identification of biomarkers that predict which patients will respond to specific treatments. For Daiichi Sankyo, this addresses a critical challenge in antibody-drug conjugate (ADC) development: these complex therapeutic modalities require precise patient selection to maximize efficacy and minimize adverse effects. By leveraging Imagene AI's dataset of 3.5 million tissue samples and omics records, Daiichi Sankyo can build more robust predictive models during clinical development, potentially accelerating approval timelines and reducing development costs.

The use of Composite Continuous Scoring for quantitative protein expression evaluation from immunohistochemistry images signals a move toward objective, AI-driven pathology assessment—a shift that may reduce variability in companion diagnostic development. This technical capability is particularly valuable for ADC programs, where target antigen expression levels directly correlate with therapeutic benefit. The stated goal of "personalized treatment for each cancer patient" reflects current industry direction toward precision oncology, and the partnership equips both organizations to pursue data-driven drug discovery at scale.